About

Hepatocellular carcinoma is the most common form of liver cancer, often arising in people with cirrhosis and ranking as a leading global cause of cancer deaths. Rivoceranib blocks tumor blood vessel growth by targeting a key signaling protein (VEGFR-2), while camrelizumab helps the immune system recognize and attack cancer cells. Together, this combination may slow tumor progression by cutting off their blood supply while boosting the body's natural defenses against the disease.